Inclusion Criteria

Inclusion criteria:

- CTCL: Biopsy-confirmed MF or SS stages IB-IVA2.

- Patients who have SS with bone marrow involvement are also eligible.

- Patients with transformed CTCL are eligible.

- ATL: Patient with cytologically or histopathologically confirmed lymphoma.

- Lymphoma should be identified as tumors derived peripheral T-cells by cell surface
marker.

- ATL: Patients with positivity for anti-HTLV-1 antibody

- Patients must have received at least two systemic therapy regimens.

- Patients must have had disease progression on or following their most recent
treatment regimen.

- Age ≥ 20 years

- ECOG Performance Status of ≤ 2

- Written informed consent obtained prior to any study specific screening procedures

Exclusion criteria:

- Patients with a history of primary CNS tumors

- Any history or presence of brain metastases

- Patients with any peripheral neuropathy ≥ CTCAE grade 2

- Patients with unresolved diarrhea > CTCAE grade 1

- Impairment of gastrointestinal (GI) function or GI disease that may significantly
alter the absorption of oral LBH589

- Patients with concurrent severe and/or uncontrolled liver or renal disease

- Patients using sodium valproate ≤5 days prior to starting study drug

- Patients with an active bleeding diathesis or on any treatment with therapeutic doses
of sodium warfarin or other antivitamin K drugs

- Patients who have received any investigational drug or chemotherapy or undergone
major surgery ≤ 3 weeks prior to starting study drug or who have not recovered from
side effects of such therapy

- Patients who have received biologic therapy, target therapy (e.g. denileukin diftitix
), vaccine, systemic steroids or immunotherapy ≤ 2 weeks prior to starting study
treatment or who have not recovered from side effects of such therapy

- Patients who have received wide field radiotherapy ≤ 4 weeks or limited field
radiation for palliation ≤ 2 weeks prior to starting study drug or who have not
recovered from side effects of such therapy